Cardiff Oncology, Inc.
NASDAQ:CRDF
3.74 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.488 | 0.386 | 0.359 | 0.366 | 0.245 | 0.378 | 0.505 | 0.381 | 0.313 | 0.28 | 0.259 | 0.45 | 0.258 | 0.266 | 0.65 | 0 | 0 |
| Cost of Revenue
| 0.398 | 0.2 | 0.5 | 11.235 | 11.162 | 0.597 | 1.811 | 1.73 | 0.629 | 0.015 | 3.481 | 1.92 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.09 | 0.186 | -0.141 | -10.869 | -10.917 | -0.219 | -1.306 | -1.349 | -0.316 | 0.265 | -3.222 | -1.47 | 0.258 | 0.266 | 0.65 | 0 | 0 |
| Gross Profit Ratio
| 0.184 | 0.482 | -0.393 | -29.697 | -44.56 | -0.579 | -2.586 | -3.541 | -1.01 | 0.946 | -12.429 | -3.267 | 1 | 1 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 32.857 | 27.107 | 17.376 | 11.235 | 11.162 | 8.164 | 7.883 | 15.007 | 10.594 | 6.665 | 3.948 | 1.92 | 0.911 | 3.691 | 0 | 1.878 | 0.62 |
| General & Administrative Expenses
| 13.043 | 13.181 | 11.838 | 8.216 | 5.761 | 8.006 | 11.497 | 11.476 | 7.92 | 5.81 | 6.757 | 3.379 | 2.324 | 0 | 2.22 | 2.531 | 0.652 |
| Selling & Marketing Expenses
| -0.398 | 0 | 0 | 0 | 0 | 0 | 2.735 | 11.523 | 6.444 | 2.735 | 0.245 | 0.507 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.645 | 13.181 | 11.838 | 8.216 | 5.761 | 8.006 | 14.232 | 22.999 | 14.364 | 8.545 | 7.002 | 3.379 | 2.324 | 1.954 | 2.22 | 2.531 | 0.652 |
| Other Expenses
| -0.098 | -0.383 | 0.015 | -0.028 | 0.002 | -0.237 | -0.17 | -0.145 | -0.003 | 0 | 0 | 0.004 | 0 | 0 | 0.83 | 0 | 0 |
| Operating Expenses
| 45.502 | 40.288 | 29.214 | 19.452 | 16.923 | 16.17 | 22.115 | 38.006 | 24.958 | 15.21 | 10.95 | 5.299 | 3.234 | 5.645 | 3.05 | 4.409 | 1.271 |
| Operating Income
| -45.412 | -39.902 | -28.855 | -19.086 | -16.678 | -17.053 | -25.596 | -40.145 | -25.274 | -14.945 | -10.691 | -4.849 | -2.977 | -5.379 | -2.39 | -8 | -5.377 |
| Operating Income Ratio
| -93.057 | -103.373 | -80.376 | -52.148 | -68.073 | -45.114 | -50.685 | -105.367 | -80.748 | -53.375 | -41.237 | -10.776 | -11.552 | -20.248 | -3.677 | 0 | 0 |
| Total Other Income Expenses Net
| 3.971 | 1.198 | 0.564 | -0.221 | 0.264 | -0.266 | -0.6 | 1.527 | -0.729 | 1.451 | -1.107 | -6.717 | 0.794 | 0.046 | -0.09 | 0.156 | 0.006 |
| Income Before Tax
| -41.441 | -38.704 | -28.291 | -19.307 | -16.414 | -16.461 | -24.907 | -39.204 | -27.471 | -14.325 | -11.811 | -11.566 | -2.277 | -5.334 | -2.48 | -7.844 | -5.371 |
| Income Before Tax Ratio
| -84.92 | -100.269 | -78.805 | -52.751 | -66.996 | -43.548 | -49.321 | -102.898 | -87.767 | -51.161 | -45.559 | -25.702 | -8.838 | -20.077 | -3.815 | 0 | 0 |
| Income Tax Expense
| 0.23 | -1.198 | -0.549 | -0.027 | -0.262 | 0.618 | 0.716 | -0.296 | 1.815 | 0.608 | 0.017 | 6.683 | -0.738 | 0.07 | -0.18 | 0 | 0 |
| Net Income
| -41.441 | -37.506 | -27.742 | -19.28 | -16.152 | -16.461 | -24.907 | -39.204 | -27.471 | -14.325 | -11.811 | -11.566 | -2.239 | -5.449 | -2.48 | -7.844 | -5.371 |
| Net Income Ratio
| -84.92 | -97.166 | -77.276 | -52.678 | -65.927 | -43.548 | -49.321 | -102.898 | -87.767 | -51.161 | -45.559 | -25.702 | -8.689 | -20.511 | -3.815 | 0 | 0 |
| EPS
| -0.93 | -0.86 | -0.71 | -0.92 | -2.7 | -7.06 | -51.71 | -93.54 | -75.49 | -54.56 | -50.27 | -63.87 | -16.6 | -54.81 | -35.43 | -0.42 | -0.37 |
| EPS Diluted
| -0.93 | -0.86 | -0.71 | -0.92 | -2.7 | -7.06 | -51.71 | -93.22 | -74.77 | -54.08 | -50.09 | -63.73 | -16.6 | -54.81 | -35.43 | -0.42 | -0.37 |
| EBITDA
| -45.014 | -39.666 | -28.689 | -18.558 | -16.212 | -15.501 | -22.343 | -39.957 | -24.548 | -14.933 | -10.556 | 1.872 | -3.761 | -5.416 | -2.52 | -8 | -5.377 |
| EBITDA Ratio
| -92.242 | -102.762 | -79.914 | -50.707 | -66.171 | -41.008 | -44.244 | -104.874 | -78.428 | -53.332 | -40.719 | 4.16 | -14.593 | -20.388 | -3.877 | 0 | 0 |